When the i-lab first opened in 2011, Vaxess Technologies, a company co-founded and led by Michael Schrader, was one of the handful of ventures that consistently showed up to work out of the new space. Last year, after a short stint at LabCentral, Schrader and Vaxess returned to Harvard's "innovation campus" on Western Avenue in Allston as part of the Pagliuca Harvard Life Lab.

Vaxess, which, had received about $6M in funding, grants, and awards combined, recently announced that it had received another $6 million grant, this time from the Gates Foundation, in order to continue developing its silk biopolymer technology and to take its innovative vaccine delivery system to clinical trials.

This is a Harvard Innovation Labs Story.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Harvard Innovation Labs. Innehållet i podden är skapat av Harvard Innovation Labs och inte av, eller tillsammans med, Poddtoppen.